Evidence map›Paper›PMID 41603250›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

RIG-I Mediated Neuron-Specific IFN Type 1 Signaling in FUS-ALS Induces Neurodegeneration and Offers New Biomarker-Driven Individualized Treatment Options for (FUS-)ALS.

Marcel Naumann, Theresa M Wierschin, Stefanie Kretschmer, Banaja P Dash, Aaron Held, Andrea Salzinger, Kevin Peikert, Anže Karlek, Hannes Glaß, Dajana Großmann and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Marcel NaumannTranslational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.
Theresa M WierschinTranslational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.
Stefanie KretschmerDepartment of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Banaja P DashTranslational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.
Aaron HeldDepartment of Neurology, Sean M. Healey & AMG Center for ALS, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
Andrea SalzingerDepartment of Neurology, Sean M. Healey & AMG Center for ALS, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
Kevin PeikertTranslational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.
Anže KarlekTranslational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.
Hannes GlaßTranslational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.
Dajana GroßmannTranslational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.
René GüntherDepartment of Neurology, University Hospital Carl Gustav Carus At Technische Universität Dresden, Dresden, Germany.
Susanne PetriDepartment of Neurology, Hannover Medical School, Hannover, Germany.
Annekathrin RödigerDepartment of Neurology, Jena University Hospital, Jena, Germany.
David BrennerDepartment of Neurology, University Hospital Ulm, Ulm, Germany.
Francisco Pan-MontojoDept. of Psychiatry and Psychotherapy at the Klinikum LMU, Munich, Germany and Neurologische Klinik Sorpesee, Sundern, Germany.
Eleonora AronicaAmsterdam UMC, University of Amsterdam, Department of (Neuro)Pathology, Amsterdam Neuroscience, Amsterdam, The Netherlands.
Markus KippCenter For Transdisciplinary Neurosciences Rostock (CTNR), University Medical Center Rostock, University of Rostock, Rostock, Germany.
Vitaly ZimyaninDepartment of Molecular Physiology and Biological Physics, School of Medicine, University of Virginia, Charlottesville, Virginia, USA.
Jared SterneckertCenter For Regenerative Therapies TU Dresden (CRTD) and the Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Torsten GrehlDepartment of Neurology, Alfried Krupp Hospital, Essen, Germany.
Noah D SeebacherInstitute of Anatomy and Cell Biology, University of Ulm, Ulm, Germany.
Tobias M BöckersInstitute of Anatomy and Cell Biology, University of Ulm, Ulm, Germany.
Alberto CataneseInstitute of Anatomy and Cell Biology, University of Ulm, Ulm, Germany.
Brian J WaingerDepartment of Neurology, Sean M. Healey & AMG Center for ALS, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA.
Patrick OecklDepartment of Neurology, University Hospital Ulm, Ulm, Germany.
Min Ae Lee-KirschDepartment of Pediatrics, Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Andreas HermannTranslational Neurodegeneration Section "Albrecht Kossel", Department of Neurology, University Medical Center Rostock, University of Rostock, Rostock, Germany.ORCID https://orcid.org/0000-0002-7364-7791

Funding

Clinician Scientist program of the Medical Faculty of the University of Rostock (RAS)German Federal Ministry of Education and Research (BMBF) 01GL2405H (DZKJ)German Federal Ministry of Education and Research (BMBF) 01GM2206C (GAIN)German Research Foundation (DFG) CRC237 369799452/A11German Research Foundation (DFG) CRC237 369799452/B21German Research Foundation (DFG) CRC369 501752319/C06Hermann und Lilly Schilling-Stiftung für Medizinische ForschungHermann und Lilly Schilling-Stiftung für Medizinische Forschung naStichting ALS NederlandStichting ALS Nederland na
6 · The paper itself

Abstract

Recent research demonstrated activation of the innate immune system in ALS models. This pathway can be activated by cGAS-STING sensing of cytosolic DNA that accumulates as a result of chronic DNA damage and defective mitochondria, both of which was identified as pathology in FUS-ALS. Therefore, we analyzed innate immune pathways in FUS-ALS, which revealed upregulation of interferon-stimulated genes (ISGs) and activation of the TBK1-IRF3 pathway in FUS

Indexed as

Amyotrophic Lateral SclerosisDEAD Box Protein 58Interferon Type IMotor NeuronsReceptors, ImmunologicBiomarkerscGAS-STING Signaling PathwayHumansImmunity, InnateSignal TransductionBiomarkersDEAD Box Protein 58Interferon Type IReceptors, ImmunologicRIGI protein, humancGAS‐STING pathwaydouble‐stranded RNApathogen‐associated molecular patternsRIG‐IRIG‐I like receptorsRNA‐sequencingtype 1 interferon

Identifiers

PMID41603250
PMCPMC13042818

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.